LENZ Therapeutics is rated a 'Strong Buy' with a fair value estimate of $21.3, suggesting about 266% upside from current stock levels. The valuation is based on projected peak US sales of $375 million for its product Vizz, assuming a 5-pack annual purchase rate and 30% market share, alongside conservative international sales assumptions. Despite the bullish outlook, risks remain due to LENZ's reliance on a single product, high selling and administrative costs, lack of insurance, and increasing competition. Short-term trading signals are mixed, but technical indicators, insider buying, and the potential for a short squeeze support a positive investment stance, though position sizes should be limited due to the speculative nature of the stock.
Mama's Creations reported a strong Q2 fiscal 2027 with revenue up 55% to $54.6 million and net income doubling to $2.6 million. The company’s growth is driven by new product launches, effective cross-selling, and inclusion in Costco's national mailer...
VinFast Auto Ltd. is set to release its Q3 2026 earnings with analysts expecting a loss per share of $0.33 and revenues around $1.15 billion. The Vietnamese electric vehicle maker is expanding internationally, promoting its VF 9 SUV in Canada and ben...
United Natural Foods (UNFI) is set to report Q4 earnings with revenue expected around $7.71 billion, a slight 1.6% decline from last year due to network optimization. Despite the revenue drop, EPS is forecasted to rise sharply to $0.61-$0.62, a signi...
XRP is approaching the $1.50 mark amid the rollout of XRPL version 3.3.0, which introduces key protocol upgrades like confidential token transfers, atomic transactions, and flexible token properties. These features aim to enhance XRPL's appeal for in...
Zcash (ZEC) surged above $1,000 on September 4, marking a significant recovery after a mid-year sell-off due to a security issue. The rally is driven by growing institutional interest, increased derivatives trading, and stronger adoption of Zcash's p...
